| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_2a819eda0adf22936a52362eeebb9fb4 |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2740-16322
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2333-163
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2500-00 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-5008
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-5011
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-5017
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K14-005 |
| classificationIPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12R1-91
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-00 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12P21-02
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N5-10
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N15-09
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K14-16
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N1-19
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N33-50
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N33-15 |
| filingDate |
1995-10-13-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_6b08729df85d5229f8ce4db745ddd7c7
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_5a721040a1417066e0918e576ab3a65f
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_3a0bc2c88de9a7a89d3d8b98bd1606e4 |
| publicationDate |
1996-04-25-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
WO-9611696-A1 |
| titleOfInvention |
Screening assay for anti-hiv drugs |
| abstract |
The essential role of the Vpr protein of HIV in the progression of HIV infection is disclosed. Recognition of this role permits assay for potential drug candidates by virtue of their ability to interfere with the interaction of Vpr with its intracellular targets. Thus, cells that are modified to contain an expression system for the production of Vpr are cultured in the presence and absence of the drug candidate and the growth rates compared. The ability of a candidate to enhance the growth of a culture producing Vpr indicates its potential as an anti-AIDS therapeutic. |
| isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-9835032-A3
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-7259014-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-6362000-B1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-6555342-B1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-9835234-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-7622300-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-7534603-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-6001985-A
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-9835032-A2 |
| priorityDate |
1994-10-13-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |